NHD Global
Reproductive & Hormone · Source-reviewed dossier
Source-Reviewed Research Dossier
Bremelanotide (PT-141) is a melanocortin-receptor agonist. The FDA-approved Vyleesi autoinjector has a narrow indication, dose, formulation and safety label; catalog PT-141 must not be represented as that approved finished product.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The U.S. label defines a 1.75 mg autoinjector and indication for selected premenopausal women with acquired, generalized HSDD.
The label does not approve catalog PT-141 material or other routes/populations.
Read the primary studyA placebo-controlled study evaluated intranasal bremelanotide in premenopausal women with sexual arousal disorder.
The study population and intranasal formulation do not establish outcomes for catalog powder or the approved autoinjector.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The label does not approve catalog PT-141 material or other routes/populations.
View primary recordThe study population and intranasal formulation do not establish outcomes for catalog powder or the approved autoinjector.
View primary recordThird-party publications selected for direct relevance.
DailyMed/FDA label.
Randomized controlled trial. 2006. PMID 16839319.
Concise answers for researchers comparing identity, evidence and catalog variants.
Bremelanotide (PT-141) is a melanocortin-receptor agonist. The FDA-approved Vyleesi autoinjector has a narrow indication, dose, formulation and safety label; catalog PT-141 must not be represented as that approved finished product.
Human pharmacology and product-specific regulatory evidence exist, with strict indication and safety boundaries.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, generalized HSDD—not men, performance…
Updated September 1, 2026
PT-141 is the development code associated with bremelanotide. A free-base peptide, its acetate form and the approved finished injection are related records, but they…
Updated September 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: P41 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
